Peanut Placebo, Nocebo, PCSK9: Lipid lowering and peanut allergy
This week: New studies of PCSK9 inhibitors for lipid lowering and a randomized controlled trial of early peanut exposure to prevent allergy
Fahad and Amol want you to understand the following:
1. PCSK9 inhibitors are new cholesterol-lowering monoclonal antibodies that have been shown to reduce LDL beyond standard therapy with statins and have been associated with reduced cardiovascular events in patients at high cardiovascular risk.
2. The LEAP study showed that early and sustained exposure to peanuts in infants at high risk of peanut allergy resulted in a reduced incidence of peanut allergy at 5 years.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.